NCT02630069

CDP-choline Treatment in ATS Users

Cytidine-5'-Diphosphate-choline Treatment in Amphetamine Type Stimulant-using Adolescents

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Ewha Womans University Mokdong Hospital · Academic / Other
• Sex: All
• Age: 14 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This study is a 12-week, randomized, double-blind, placebo-controlled trial of cytidine-5'-diphosphate choline in amphetamine-type stimulants-using adolescents.

Detailed description

This study is a 12-week, randomized, double-blind, placebo-controlled trial of cytidine-5'-diphosphate choline (CDP-choline) in amphetamine-type stimulants-using adolescents. Multi-level assessments will be performed to determine whether CDP-choline administration with supportive psychotherapy, compared to placebo administration with supportive psychotherapy, will 1) repair ATS-induced neural cell damage of the target brain regions, 2) improve cognitive deficits and normalize the relevant target neural circuits, and then 3) reduce ATS-taking behaviors in ATS-using adolescents.

Conditions

• Substance Use Disorders

Interventions

Type	Name	Description
DRUG	CDP-choline	CDP-choline 500mg once a day for 12 weeks
DRUG	Placebo	Placebo 500mg once a day for 12 weeks
BEHAVIORAL	Supportive psychotherapy	Supportive psychotherapy 1 session/2 weeks for 12 weeks

Timeline

• Start date: 2015-03-01
• Primary completion: 2022-12-01
• Completion: 2022-12-01
• First posted: 2015-12-15
• Last updated: 2022-08-01

Locations

1 site across 1 country: South Korea